SciVision Biotech has products in four high-end medical device fields, including HA dermal filler in the facial aesthetic field, absorbable adhesion barrier in the surgery field, synovial fluid supplement for the field of elderly care, and intravesical instillation in the field of urology. We provide comprehensive care for the beauty and health of the human race.
SciVision adheres to a concept and spirit of continuous innovation to create a better vision for the human race.
More
See You at Medical Taiwan 2026! SciVision Biotech is excited to participate in Medical Taiwan 2026 this June in Taipei! As one of Asia’s key healthcare and medical technology exhibitions, Medical Taiwan brings together professionals and innovators from across the industry. We’re looking forward to sharing our latest developments and connecting with partners from around the world. Booth No. D0724 June 25–27, 2026 TWTC Exhibition Hall 1, Taipei ,Taiwan Stop by our booth and explore new possibilities in healthcare innovation with us We can’t wait to meet you in person!
more
WHX Miami is just around the corner! We are excited to announce our participation to one of the leading medical device exhibition held at Miami Beach Convention Center in the United States on June 17-19. We are looking forward to showcase innovations we are currently working on and find new potential opportunities in the fast-paced Latin American market. Our booth is #S51. Feel free to stop by our booth and to discuss the latest hyaluronic acid technologies with us! Booth: S51 June 17–19, 2026 Miami Beach Convention Center See you in Miami
more
A New Milestone for SciVision As the aesthetic medical industry enters the MDR era, only a limited number of manufacturers worldwide have successfully achieved certification under the European Union Medical Device Regulation (MDR). We are proud to announce that SciVision Biotech has officially obtained CE certification under the MDR framework for our Class III non-lidocaine dermal filler products. This achievement reflects our long-term commitment to product quality, patient safety, regulatory excellence, and international standards. The MDR certification marks another important milestone in SciVision’s global development and further strengthens our dedication to providing safe, innovative, and high-quality medical aesthetic solutions to healthcare professionals and patients worldwide.
more
SciVision Biotech Inc. has been granted a Taiwan invention patent (Patent No. I920698), titled “Method for Manufacturing Crosslinked Hyaluronic Acid Gel Containing Triamcinolone and Crosslinked Hyaluronic Acid Gel Thereof.” This patented technology is designed for the production of triamcinolone-containing crosslinked hyaluronic acid (HA) gels intended for the treatment of osteoarthritis patients. Triamcinolone is a type of corticosteroid commonly used in intra-articular injections to relieve inflammation and pain associated with osteoarthritis. Corticosteroids may be naturally produced by the adrenal cortex or synthetically manufactured for medical applications. When combined with crosslinked hyaluronic acid for joint injection, the therapeutic effect can be further enhanced. Corticosteroids are known to provide rapid pain relief during the first few days following injection. Leveraging SciVision’s proprietary CHAP crosslinking platform technology together with its newly developed uniform particle dispersion technology, triamcinolone can be evenly distributed throughout the crosslinked HA gel matrix. The resulting formulation enables sustained drug release, thereby prolonging the anti-inflammatory and analgesic effects of the corticosteroid. This invention patent represents a key technological advancement in drug-device combination products based on crosslinked hyaluronic acid matrices. The newly granted patent marks a significant breakthrough for SciVision in the development and manufacturing of HA-based drug-containing products. The patent scope covers both manufacturing methods and composition claims, providing strong protection against competitive development of similar products and further strengthening SciVision’s leadership position in the hyaluronic acid market.
moreThis website uses browser records (Cookies) to provide you with the best experience. The Cookies we use also include third-party Cookies.
For related information, please visit ourprivacy policy. If you choose to continue browsing or close this prompt, you agree to our terms of website use.
